A Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A pilot investigation into the stress relieving properties of Vitano® which will assess the following hypotheses
Individuals exposed to Vitano® will demonstrate diminished blood pressure and heart rate responses to mental stress compared to individuals in the control condition
Physiological recovery (BP, HR and cortisol) from mental stress will be enhanced in individuals exposed to Vitano® compared to individuals in the control condition
Vitano® will have positive effects on cognitive functioning.
Subjective ratings of stress will be reduced in individuals exposed to Vitano® compared to individuals in the control condition
There will be a significant improvement in subjective well-being in individuals taking Vitano®.
| Condition | Intervention | Phase |
|---|---|---|
|
Mild Stress/Anxiety |
Drug: Vitano |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Pilot Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress Assessed Under Laboratory Conditions And In Everyday Life |
- Blood pressure measurements [ Time Frame: Measurements over 14 days (Day 0, Day 7 and Day 14) ] [ Designated as safety issue: No ]Blood pressure readings taken under laboratory conditions during cognitive testing and relaxation periods
- Measures of cognitive function [ Time Frame: 14 days ] [ Designated as safety issue: No ]cognitive function assessed four times during the 14 day study period
| Enrollment: | 80 |
| Study Start Date: | January 2011 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Vitano |
Drug: Vitano
two 200mg tablets per day for 14 days
|
|
No Intervention: Control
No tablets - control group
|
Drug: Vitano
two 200mg tablets per day for 14 days
|
Eligibility| Ages Eligible for Study: | 18 Years to 35 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- subject is able to read and understand the Informed Consent Form (ICF), and understand study procedures.
- The subject has signed the ICF.
- Healthy male or female subjects aged 18-35 years inclusive. Attempts will be made to achieve an equal gender ratio through appropriate screening procedures, but a failure to do so will not preclude analysis of the final data set.
- A score above 30 on the Spielberger State-Trait Anxiety Inventory (STAI).
- The subject agrees to use suitable methods of contraception during the study and for 3 months afterwards.
- The subject is a non-smoker.
- The subject is, in the opinion of the Investigator, healthy on the basis of medical history, vital signs, and the results of routine laboratory tests.
Exclusion Criteria:
- The subject is pregnant or breast feeding.
- The subject consumes more than 5 caffeine-containing beverages per day.
- The subject is colour blind.
- Clinically significant hepatic or renal abnormality as determined by laboratory tests.
- BMI above 33.
- History of alcohol, narcotic, benzodiazepine, or other substance abuse or dependence within the 12 months preceding Visit 1.
- Positive alcohol breath test at any visit. A repeat test will not be allowed. [NOTE: subjects must be told to avoid consumption of alcoholic beverages for at least 24 hours prior to attending the Centre].
- Use of any other medication which may interfere with study outcome and/or interfere with IMP within the 2 weeks or 5 half lives preceding the first treatment phase, with the exception of contraceptive pill, non-steroidal analgesics, and paracetamol. [NOTE: Concomitant medications which do not influence study outcome and/or do not interfere with IMP may be allowed at the discretion of the Investigator].
- Current participation in another clinical trial with an investigational or non-investigational drug or device, or participation in another clinical trial within the 3 months preceding Visit 1 (screening visit).
- Any condition that, in the Investigator's opinion, compromises the subject's ability to meet protocol requirements or to complete the study.
- Moderate or severe anxiety* *If participants are found to have moderate or severe anxiety during the screening process then they will be referred to the University Counselling service.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Dr Hubert Bland, University of Surrey |
| ClinicalTrials.gov Identifier: | NCT01411709 History of Changes |
| Other Study ID Numbers: | CRC287 |
| Study First Received: | July 28, 2011 |
| Last Updated: | August 5, 2011 |
| Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Additional relevant MeSH terms:
|
Anxiety Disorders Stress, Psychological Mental Disorders Behavioral Symptoms |
ClinicalTrials.gov processed this record on June 17, 2013